Page last updated: 2024-11-05

niridazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Niridazole: An antischistosomal agent that has become obsolete. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6093
CHEMBL ID152632
CHEBI ID82349
SCHEMBL ID126396
MeSH IDM0014868

Synonyms (89)

Synonym
OPREA1_249644
smr001233194
MLS002153826
BRD-K53123955-001-03-0
ntoi
mls002920381 ,
nsc-136947
1-(5-nitro-2-thiazolyl)-2-oxotetrahydroimidazole
ba 32644
1-(5-nitro-2-thiazolyl)imidazolidin-2-one
nsc136947
61-57-4
1-(5-nitro-2-thiazolyl)-2-oxotetrahydroimidazol
nitrothiazole
2-imidazolidinone, 1-(5-nitro-2-thiazolyl)-
nitrothiazol
1-(5-nitro-2-thiazolyl)-2-imidazolinone
wln: t5n csj dnw b- ct5mvntj
nitrothiamidazole
niridazole
nitridazole
ciba 32644
ciba 32644-ba
ambilhar
1-(5-nitro-2-thiazolyl)-2-imidazolidinone
nitrothiamidazol
einecs 200-512-6
niridazole [usan:inn:ban]
ccris 434
ba 32644 ciba
hsdb 7480
niridazol [inn-spanish]
ai3-51833
brn 0665338
nsc 136947
niridazolum [inn-latin]
BSPBIO_000578
PRESTWICK_543
cas-61-57-4
NCGC00016277-01
BPBIO1_000636
D05170
niridazole (usan/inn)
PRESTWICK3_000469
1-(5-nitro-thiazol-2-yl)-imidazolidin-2-one
1-(5-nitrothiazol-2-yl)imidazolidin-2-one
AB00513844
PRESTWICK2_000469
PRESTWICK0_000469
PRESTWICK1_000469
SPBIO_002517
NCGC00016277-02
niridazolum
chebi:82349 ,
ba-32644
ciba 32644ba
CHEMBL152632
HMS1569M20
1-(5-nitro-1,3-thiazol-2-yl)imidazolidin-2-one
HMS2096M20
C19268
dtxcid4025244
tox21_110343
dtxsid6045244 ,
niridazol
HMS2231C14
unii-n116u8y5qq
n116u8y5qq ,
HMS3374G02
niridazole [mi]
niridazolum [who-ip latin]
niridazole [who-dd]
niridazole [inn]
niridazole [mart.]
niridazole [who-ip]
niridazole [iarc]
niridazole [hsdb]
niridazole [usan]
CCG-220469
SCHEMBL126396
1-(5-nitro-2-thiazolyl)-2-imidazolidone
1-(5-nitro-1,3-thiazol-2-yl)-2-imidazolidinone #
RDXLYGJSWZYTFJ-UHFFFAOYSA-N
sr-01000838830
SR-01000838830-2
HMS3713M20
DB13661
Q7039974
AKOS040749027

Research Excerpts

Overview

Niridazole is a nitrothiazole anthelmintic agent used to treat schistosomiasis. It was shown to be an effective chemotherapeutic agent for mice infected intravenously with a nirodazole-sensitive strain of Salmonella typhimurium.

ExcerptReferenceRelevance
"Niridazole is a nitrothiazole anthelmintic agent used to treat schistosomiasis. "( Relative importance of bacterial and mammalian nitroreductases for niridazole mutagenesis.
Blumer, JL; Fairchild, E; Friedman, A; Meyer, LW; Speck, WT; Webster, LT, 1980
)
1.94
"Niridazole was shown to be an effective chemotherapeutic agent for mice infected intravenously with a niridazole-sensitive strain of Salmonella typhimurium. "( Antibacterial effects of niridazole. I. Effect on infection of mice with Salmonella typhimurium.
Heine, WD; Hof, H; Müller, KM, 1982
)
2.01
"Niridazole is a potent inhibitor of certain expressions of delayed-type hypersensitivity; however, its effect and specificity on other immunologically induced mononuclear cell infiltrates has not been determined. "( Studies on the pathogenesis of experimental autoimmune renal tubulointerstitial disease in guinea-pigs. IV. failure to inhibit mononuclear cell accumulation with niridazole.
Pollara, B; Rudofsky, UH, 1977
)
1.9
"Niridazole is an effective schistosomicidal compound which, at lower dose levels, affects schistosome gonads. "( Comparative effects of niridazole on spermatogenesis and reproductive capacity in the mouse, rat and Japanese quail.
Jackson, H; Jones, P; Whiting, MH, 1976
)
2.01

Treatment

Niridazole inhibits T-cell mediated immunity, did not alone or in combination with cyclophosphamide affect the resistance pattern after immunization. Mice treated with niridzole daily, but not those treated on alternate days, showed a significant reduction in the inflammatory reaction to larvae in the muscles.

ExcerptReferenceRelevance
"Niridazole treatment reduced the growth of S."( Effect of oral niridazole treatment on some bacterial infections in mice.
Collins, FM, 1975
)
1.33
"Niridazole-treated (100 mg/kg) and untreated guineapigs were injected with potent anti-tubular basement membrane serum from donors with RTD."( Studies on the pathogenesis of experimental autoimmune renal tubulointerstitial disease in guinea-pigs. IV. failure to inhibit mononuclear cell accumulation with niridazole.
Pollara, B; Rudofsky, UH, 1977
)
1.17
"Niridazole-treated mice were free of any foci 10 days after the last treatment and no adult worms were recovered on perfusion of the hepatic portal system relative to control mice from which 5.8% of the infective cercariae were recovered as adult worms at Day 42 post-infection."( Autoradiographic quantification of the efficacy of niridazole in mice infected with 75Se-labelled cercariae of Schistosoma mansoni.
Waruiru, RM, 1992
)
1.26
"(4) Treatment with niridazole, which inhibits T-cell mediated immunity, did not alone or in combination with cyclophosphamide affect the resistance pattern after immunization."( Experimental Escherichia coli 06 infection in mice. II. Protective factors of immunity after immunosuppression.
Ahlstedt, S, 1980
)
0.58
"Mice treated with niridazole daily, but not those treated on alternate days, showed a significant reduction in the inflammatory reaction to larvae in the muscles."( Effects on murine trichinosis of niridazole, a suppressant of cellular but not humoral immunological responses.
Grove, DI; Warren, KS, 1976
)
0.86

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Niridazole in an oral dosage of 10 mg/kg reduced (but did not eliminate) tuberculin hypersensitivity in the mycobacteria-infected mice. Drug combinations incorporating niridzole at a lower dosage or for a shorter period were less effective, and azathioprine and prednisolone prolonged graft survival only marginally.

ExcerptRelevanceReference
" Niridazole in an oral dosage of 10 mg/kg reduced (but did not eliminate) tuberculin hypersensitivity in the mycobacteria-infected mice."( Effect of oral niridazole treatment on some bacterial infections in mice.
Collins, FM, 1975
)
1.52
" The mechanism of action, dose-response dependency, effect of timing, and relation to bacterial adjuvanticity need more thorough exploration."( [Immunosuppression as a concomitant effect].
Floersheim, GL, 1978
)
0.26
" Drug combinations incorporating niridazole at a lower dosage or for a shorter period were less effective, and azathioprine and prednisolone on their own or used together prolonged graft survival only marginally in this model."( Prolonged allograft survival with niridazole, azathioprine, and prednisolone.
Bird, M; Godfrey, AM; Jones, B; Millar, D; Miller, J; Salaman, JR, 1977
)
0.82
" When given orally at a dosage of 50 mg/kg it extended the median survival of cardiac allografts from 7 to 20 days."( Niridazole as an immunosuppressive agent.
Bird, M; Godfrey, AM; Jones, B; Millar, D; Miller, J; Salaman, JR, 1977
)
1.7
" in mice and hamsters was 50 mg/kg body weight after a single oral dose and 20 or 50 mg/kg body weight respectively when dosed once daily on 5 consecutive days."( [Experimental studies on the schistosomicidal activity of the aminobenzaldehyde derivative 80.647 (author's transl)].
Ascher, G; Hildebrandt, J; Mieth, H; Reinshagen, H, 1977
)
0.26
" In vivo, niridazole showed a stimulatory effect on the rate of gluconeogenesis from alpha-ketoglutarate and on the rate of oxidation of pyruvate at a dosage level of 100 mg/kg for 5 days."( Biochemical effects of niridazole. I. In vitro and in vivo effect of niridazole on the rate of gluconeogenesis and oxidation of pyruvate and some Krebs cycle intermediates in mice.
Kassem, F; Khayyal, MT; Kheir-el-Din, A; Sharaf, AA, 1978
)
0.97
" low dosage only) the rate of gluconeogenesis from pyruvate and alpha-ketoglutarate was stimulated."( Biochemical effects of niridazole. II. In vitro and in vivo effects of niridazole on the rate of gluconeogenesis and the rate of oxidation of pyruvate and some Krebs cycle intermediates in Schistosoma mansoni infected mice.
Kassem, F; Khayyal, MT; Kheir-el-Din, A; Sharaf, AA, 1978
)
0.57
"Niridazole was administered by gavage to 5-week-old chickens at dosage levels of 50, 100, and 200 mg/kg of body weight."( Evaluation of niridazole as a suppressant of cellular immunity in chickens.
Walser, MM, 1978
)
2.06
" Niridazole appears to be non-mutagenic since dominant lethal mutations were not produced in dose-response studies."( Comparative effects of niridazole on spermatogenesis and reproductive capacity in the mouse, rat and Japanese quail.
Jackson, H; Jones, P; Whiting, MH, 1976
)
1.48
" Azathioprine dosage correlated negatively with post-transplantation polycythaemia regardless of the original cause of renal failure."( Polycythaemia following renal transplantation: an association with azathioprine dosage?
Hutton, RD; Newcombe, RG; Orchard, J; Price, KA; Salaman, JR; Webb, DB, 1987
)
0.27
" Nitrofurantoin failed to elicit this unusual malformation but exhibited an extremely steep dose-response curve for embryolethality."( On the capacity of nitroheterocyclic compounds to elicit an unusual axial asymmetry in cultured rat embryos.
Fantel, AG; Greenaway, JC; Juchau, MR, 1986
)
0.27
" The results showed that administration of ambilhar to rats dosed with mercuric chloride, resulted in a significant increase in the faecal excretion of mercury."( On the effects of ambilhar on mobilisation and biliary excretion of mercury.
Abdel Aziz, FT; Abdel-Rahim, A; Al-Tamer, YY; Bashi, AD, 1982
)
0.26
"The effects of Astiban, Lucanthone, Hycanthone and Niridazole on autophagic activities in the gastrodermis of Schistosoma mansoni were determined in vivo, using different dosage levels and dosage times."( Schistosoma mansoni: an in vivo study of drug-induced autophagy in the gastrodermis.
Clarkson, J; Erasmus, DA, 1984
)
0.52
" We selected a dosage of 10 mg/kg of metrifonate and 25 mg/kg of niridazole."( [Comparative efficacy of oltipraz (1 dose, 30 mg/kg) and the combination of niridazole (25 mg/kg) and metrifonate (10 mg/kg) against S. haematobium].
Mouchet, F; Rey, JL; Sellin, B; Sellin, E; Simonkovich, E,
)
0.6
" The results showed that administration of ambilhar to guinea pigs dosed with lead acetate resulted in a significant decrease in the liver content of lead with a concomitant increase in urinary and faecal lead excretion."( Some studies on the effects of ambilhar on mobilisation and excretion of lead.
Abdel Aziz, FT; Al-Khayat, TM, 1981
)
0.26
" dosage range was chosen so that the lethal effect, ascribed to central nervous system toxicity, did not occur before 4 to 5 days."( Toxicogenetics of niridazole in inbred mice.
Blumer, JL; Lucas, SV; Simpson, JM; Webster, LT, 1980
)
0.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
1,3-thiazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency3.98110.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency3.98110.025120.237639.8107AID886
USP1 protein, partialHomo sapiens (human)Potency7.94330.031637.5844354.8130AID504865
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.84890.001318.074339.8107AID926
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency39.81070.425612.059128.1838AID504891
gemininHomo sapiens (human)Potency35.48130.004611.374133.4983AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency10.00000.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency0.39810.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency0.39811.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency0.39811.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency0.39811.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency0.39811.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency0.39811.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency0.39811.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency0.39811.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency0.39811.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.39811.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency0.39811.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency0.39811.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency0.39811.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency0.39811.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.39811.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency0.39811.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency0.39811.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (60)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID194146The total 72 hr urinary excretion of unchanged compound reported as log (percent X 10) of the administered dose1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID23681Partition coefficient (logP)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID194145The total 54 h urinary excretion of unchanged compound reported as log (percent X 10) of the administered dose1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID172618The amount of unchanged compound detected in urine collected at 0-18 hr after treatment1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID224799The amount of the unchanged form of compound detected in the urine samples collected at 0-18 hr after the treatment by HPLC technique; No data1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID172620The amount of unchanged compound in urine collected at 0-36 hr after treatment1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID194142The total 18 hr urinary excretion of the unchanged form of compound in urine was reported as log (percent X 10) of the administered dose by HPLC technique; No data1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID1137170Antischistosomal activity against Schistosoma mansoni Puerto Rican infected mouse assessed as reduction in live schistosomes at 249 mg/kg/day, through diet for 14 days1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antischistosomal effects of 5-(2,4,5-trichlorophenyl)hydantoin and related compounds.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID194143The total 18 hr urinary excretion of unchanged compound reported as log (percent X 10) of the administered dose1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID23442Partition coefficient (logP)1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID194144The total 36 hr urinary excretion of unchanged compound reported as log (percent X 10) of the administered dose1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1137147Antischistosomal activity against Schistosoma mansoni Puerto Rican infected mouse assessed as infected mouse at 249 mg/kg/day, through diet for 14 days1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antischistosomal effects of 5-(2,4,5-trichlorophenyl)hydantoin and related compounds.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID26535Capacity factor (log k')1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID200690Mutagenic activity in an Ames test on Salmonella Typhimurium TA98; Activity is log of revertants/nmol1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
AID172621The amount of unchanged compound in urine collected at 0-54 hr after treatment1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID172622The amount of unchanged compound in urine collected at 0-72 h after treatment1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (380)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990353 (92.89)18.7374
1990's10 (2.63)18.2507
2000's4 (1.05)29.6817
2010's9 (2.37)24.3611
2020's4 (1.05)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.12 (24.57)
Research Supply Index6.10 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index52.19 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials22 (5.21%)5.53%
Reviews28 (6.64%)6.00%
Case Studies39 (9.24%)4.05%
Observational0 (0.00%)0.25%
Other333 (78.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]